NYSEAMERICAN:ARMP Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free ARMP Stock Alerts $2.76 +0.23 (+9.09%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.49▼$2.8050-Day Range N/A52-Week Range$1.07▼$5.26Volume9,511 shsAverage Volume12,613 shsMarket Capitalization$99.77 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Get Armata Pharmaceuticals alerts: Email Address Armata Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside153.6% Upside$7.00 Price TargetShort InterestHealthy0.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.34) to ($1.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.14 out of 5 stars 3.5 Analyst's Opinion Consensus RatingArmata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageArmata Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.09% of the float of Armata Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArmata Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Armata Pharmaceuticals has recently decreased by 30.28%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArmata Pharmaceuticals does not currently pay a dividend.Dividend GrowthArmata Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARMP. Previous Next 2.8 News and Social Media Coverage News SentimentArmata Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Armata Pharmaceuticals this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders85.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.57% of the stock of Armata Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Armata Pharmaceuticals are expected to grow in the coming year, from ($1.34) to ($1.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Armata Pharmaceuticals is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Armata Pharmaceuticals is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP)Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.Read More ARMP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARMP Stock News HeadlinesMarch 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Armata Pharmaceuticals Amid Progress in Bacteriophage Therapy DevelopmentMarch 23, 2024 | finance.yahoo.comArmata Pharmaceuticals Inc (ARMP) Earnings: Navigates Through R&D to Narrow LossesApril 28, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Armata Pharmaceuticals Amid Clinical Progress and Strategic GrowthMarch 22, 2024 | finanznachrichten.deArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate UpdateMarch 21, 2024 | finance.yahoo.comArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate UpdateMarch 15, 2024 | finance.yahoo.comINVA Apr 2024 15.000 callMarch 10, 2024 | finance.yahoo.comINVA Mar 2024 7.500 callApril 28, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. March 6, 2024 | investing.comArmata secures $35 million to fund phage therapy trialsMarch 4, 2024 | finance.yahoo.comArmata Pharmaceuticals Announces $35 Million Secured Credit Agreement with InnovivaFebruary 21, 2024 | finance.yahoo.comArmata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy SummitFebruary 21, 2024 | prnewswire.comArmata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy SummitFebruary 10, 2024 | investing.comArmata Pharmaceuticals Inc (ARMP)February 2, 2024 | morningstar.comArmata Pharmaceuticals Inc ARMPNovember 15, 2023 | markets.businessinsider.comRobust Advancements and Strategic Planning: Key Drivers for Armata Pharmaceuticals’ Buy RatingNovember 15, 2023 | finance.yahoo.comArmata Pharmaceuticals Inc (ARMP) Reports Q3 2023 Financial Results and Corporate UpdatesNovember 15, 2023 | finanznachrichten.deArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate UpdateNovember 14, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate UpdateNovember 6, 2023 | money.usnews.comLexeo Therapeutics Inc.October 30, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis ConferenceOctober 19, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023October 4, 2023 | msn.comArmata Pharmaceuticals (ARMP) Price Target Increased by 14.29% to 8.16September 28, 2023 | markets.businessinsider.comArmata Pharmaceuticals: Promising Clinical Trials and New Leadership Bolster Buy RecommendationSeptember 26, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureusSeptember 21, 2023 | finance.yahoo.comArmata Pharmaceuticals to Participate in the Cantor Global Healthcare ConferenceAugust 22, 2023 | uk.news.yahoo.comArmata Pharma (ARMP) Stock Surges 130% in a Month: Here's WhySee More Headlines Receive ARMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSEAMERICAN:ARMP CUSIPN/A CIKN/A Webwww.armatapharma.com Phone(310) 655-2928Fax310-665-2963Employees66Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+153.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,040,000.00 Net Margins-1,524.51% Pretax Margin-1,524.51% Return on Equity-280.95% Return on Assets-52.61% Debt Debt-to-Equity RatioN/A Current Ratio1.16 Quick Ratio1.16 Sales & Book Value Annual Sales$4.53 million Price / Sales22.03 Cash FlowN/A Price / Cash FlowN/A Book Value($0.89) per share Price / Book-3.10Miscellaneous Outstanding Shares36,150,000Free Float5,242,000Market Cap$99.77 million OptionableNot Optionable Beta0.85 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Mina Pastagia M.D. (Age 49)MS, Chief Medical Officer Comp: $537.6kDr. Deborah L. Birx M.D. (Age 67)CEO & Director Mr. Richard Rychlik (Age 68)VP, Corporate Controller & Principal Financial Officer Mr. Peter HubbardVice President of OperationsDr. Pierre Kyme Ph.D.Senior Vice President of Business & Corporate DevelopmentKey CompetitorsCurisNASDAQ:CRISProtalix BioTherapeuticsNYSE:PLXAtara BiotherapeuticsNASDAQ:ATRAAlloVirNASDAQ:ALVRSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInstitutional OwnershipSeaCrest Wealth Management LLCBought 14,647 shares on 4/18/2024Ownership: 0.091%View All Institutional Transactions ARMP Stock Analysis - Frequently Asked Questions Should I buy or sell Armata Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ARMP shares. View ARMP analyst ratings or view top-rated stocks. What is Armata Pharmaceuticals' stock price target for 2024? 1 brokerages have issued 12-month target prices for Armata Pharmaceuticals' shares. Their ARMP share price targets range from $7.00 to $7.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 153.6% from the stock's current price. View analysts price targets for ARMP or view top-rated stocks among Wall Street analysts. Are investors shorting Armata Pharmaceuticals? Armata Pharmaceuticals saw a decrease in short interest in April. As of April 15th, there was short interest totaling 9,900 shares, a decrease of 30.3% from the March 31st total of 14,200 shares. Based on an average trading volume of 15,600 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.1% of the company's shares are sold short. View Armata Pharmaceuticals' Short Interest. When is Armata Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ARMP earnings forecast. How were Armata Pharmaceuticals' earnings last quarter? Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) issued its earnings results on Thursday, March, 21st. The company reported ($0.55) earnings per share (EPS) for the quarter. The business had revenue of $1.53 million for the quarter, compared to the consensus estimate of $0.68 million. Armata Pharmaceuticals had a negative net margin of 1,524.51% and a negative trailing twelve-month return on equity of 280.95%. What other stocks do shareholders of Armata Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), Micron Technology (MU), Aduro Biotech (ADRO), Occidental Petroleum (OXY) and Gilead Sciences (GILD). Who are Armata Pharmaceuticals' major shareholders? Armata Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include SeaCrest Wealth Management LLC (0.09%). View institutional ownership trends. How do I buy shares of Armata Pharmaceuticals? Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:ARMP) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Armata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
